Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 2Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × enasidenib × 90 days × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡